FTC and states sue Hims & Hers; stock drops amid investigation
Aug 14, 2026, 2:33 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Regulatory actions and lawsuits create near-term downside risk via penalties, required disclosures, and revenue impact; past cases show stock reacts to regulatory actions regardless of ultimate outcomes (e.g., fines or settlements in tech/health sectors).
AI summary
What happened, with direct paths to the underlying reporting
Regulators allege Hims & Hers misled about prescription charges and privacy practices, while restricting cancellation. The FTC, California, and Utah sue in the Northern District of California; Kaplan Fox has launched its own securities investigation. The stock fell about 14.7% on July 29, 2026, signaling investor concern and potential additional disclosures or settlements.
FTC and California/Utah actions allege Hims misled on prescription charges. Privacy concerns cited.
Stock dropped 14.73% to $25.00 on July 29, 2026.
Kaplan Fox & Kilsheimer LLP launched the securities investigation.
FTC alleges data sharing with Meta and Snap; broader privacy scrutiny.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Regulators allege Hims & Hers misled customers about prescription charges and privacy, and the company allegedly shared health data with third parties. The July 29 FTC suit, follo…
Hims & Hers Health reported stronger-than-expected Q2 revenue and lifted its full-year revenue guidance, driven by subscriber growth and the expansion of personalized healthcare o…
The FTC has filed suit against Hims & Hers alleging the telehealth platform shared users' health data with online advertisers despite privacy promises and engaged in deceptive bil…
Hims & Hers Health could benefit if U.S. regulators loosen peptide manufacturing rules, unlocking a multi-billion-dollar market. The catalyst depends on regulatory timing and prod…